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Genotype tunes PDAC tension to drive matricellular-enriched fibrosis and tumor 
aggression  
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Abstract 
The fibrotic phenotype of pancreatic ductal carcinoma contributes to patient mortality. 
Nevertheless, anti-stromal therapies have had mixed results, suggesting there are multifaceted, 
anti and pro-tumorigenic roles for fibrosis. We found that the genotype of pancreatic ductal 
carcinomas tunes the tension of the malignant epithelium to mechanically prime the stroma and 
promote tumor progression through epithelial pSTAT3 and YAP. Kras pancreatic tumors in mice 
lacking epithelial TGF  signaling developed a highly stiff, matricellular-enriched fibrosis and 
exhibited increased epithelial myosin activity with elevated cytokine, Jak, Rock, Fak and Yap 
signaling, and Stat3-dependent inflammation. Increasing pancreatic epithelial mechanosignaling 
accelerated Kras-dependent transformation that was accompanied by stromal stiffening and a 
matricellular-enriched fibrosis with high epithelial Yap and pStat3 activity. Elevating pStat3 
increased tissue tension and matricellular-enriched fibrosis and activated Yap to accelerate Kras-
dependent pancreatic transformation. By contrast, epithelial Stat3 ablation attenuated pancreatic 
malignancy and reduced the matricellular-enriched fibrosis, stromal stiffening, epithelial 
contractility and Yap activation induced by Kras/TGF  knockout. Tissue arrays revealed that the 
least differentiated human pancreatic tumors from patients with the shortest survival had 
matricellular-enriched fibrosis and a highly contractile, mesenchymal-like epithelium that lacked 
pSMAD and had elevated pSTAT3, YAP and SOX2. Our data underscore the importance of 
tumor genotype in tuning stromal-epithelial interactions and illustrate how tissue tension can 
force malignancy, drive tumor aggression and compromise patient survival. 
  
Introduction 
Pancreatic ductal adenocarcinomas (PDACs) are profoundly fibrotic and PDAC patients have a 
high mortality rate1. PDAC fibrosis induces interstitial fluid pressure to disrupt blood vessel 
integrity and induce hypoxia that compromise drug delivery and promote disease aggression and 
therapy resistance2 5. Consequently, considerable resources have been expended to develop 
strategies to reduce PDAC fibrosis6. To this end, inhibition of stromal sonic hedgehog (SHH) 
signaling in a mouse model of PDAC significantly reduced fibrosis and increased intratumoral 
vascular density to increase drug update that, at least transiently, stabilized the disease7. 
Similarly, reducing mouse pancreatic tumor hyaluronan, using hyaluronidase, or treating 
xenografted human pancreatic tumors with an angiotensin inhibitor to reduce tissue tension, 
decreased interstitial fluid pressure and normalized the vasculature to facilitate chemotherapy 
response8,9. Yet, phase II clinical trials in PDAC patients treated with the SHH inhibitors IPI-926 
or GDC-0449, or with a monoclonal antibody against the collagen cross-linking enzyme LOXL2, 
failed (NCT01472198)10. Experiments in mouse models of PDAC revealed that, while depletion 
of proliferating -smooth muscle actin ( SMA) positive stromal cells reduced fibrosis, the 
vasculature remained abnormal and the tumor, while smaller, was hypoxic and less 
differentiated, with accelerated mortality11. Despite a frank reduction in fibrosis and 
enhancement of tissue vascularity, genetic ablation of SHH or treatment with a smoothened 
inhibitor induced mouse PDACs that were less differentiated and more, not less, aggressive12. 
These data imply that the stroma can both promote and restrain tumor progression, and suggest 
stromal dependency may be context dependent. Whether such complexity could be explained by 
distinct tumor genotype - stromal interactions or by the natural evolution of PDACs  remains 
unclear.  
 Malignant transformation of an epithelial tissue is universally accompanied by 
extracellular matrix (ECM) deposition and remodeling13,14. Nevertheless, the extent and nature of 
the fibrosis and the responsiveness of the transformed epithelium to the desmoplastic ECM can 
vary widely across cancers, amongst tumor subtypes and even within one tumor15 18. Indeed, the 
fibrotic response in patients with aggressive, treatment-resistant, quasi-mesenchymal PDACs 
(QM-PDA) is less prominent and tumor cells isolated from QM-PDA patients are only 
marginally anchorage-dependent for their growth and survival19,20. By contrast, patients with 
classical PDACs have a better prognosis and classical PDACs are more differentiated, and tumor 
cells isolated from these cancers retain Ras dependence and express higher levels of cell 
adhesion molecules11,21. Although the origins of the QM and classical histophenotypes have yet 
to be determined, PDAC development has been irrevocably linked to a handful of genetic 
modifications. Thus, pre-malignant pancreatic lesions (PanINs) frequently possess activating 
point mutations in the Kras proto-oncogene and PDAC progression correlates with either the 
genetic and/or epigenetic inactivation of the tumor suppressor genes p16INK4a ( 90%), p53 
( 75%) and SMAD4 (DPC4, 55%)22. Consistently, genetically-engineered mouse models 
(GEMMs) in which an activated Kras is expressed in the pancreatic ductal epithelium develop 
PanINS and when combined with deletion of a single allele of p53, p16INK4a, Smad4 or Tgfbr2 
develop PDACs23 26. Of these genetic modifications, mice with combined Kras mutations and 
Tgfbr2 deletion are very aggressive and exhibit a mesenchymal-like phenotype following 
stromal ablation11,23. Moreover, the human mesenchymal-like PDAC phenotype most frequently 
associates with aberrant TGF  signaling in the epithelium27. These findings imply that distinct 
genotypes may dictate unique stromal-epithelial phenotypes. Importantly, as mouse PDACs 
develop they also increase expression of mesenchymal-like features, as do patients with recurrent 
PDACs, and ablation of proliferating alpha smooth muscle actin ( SMA) positive cells in 
Kras/p53 mouse PDAC permits the expansion of mesenchymal-like, aggressive tumors28 30. 
These observations suggest that the epithelium likely evolves over time towards a less stromally-
dependent phenotype and imply that this evolution may be linked to the engagement of pathways 
that promote a mesenchymal-like transition.   
 High grade PDACs express more Sex-determining region Y (SRY)-Box2 (SOX2), a 
transcription factor that drives an epithelial-to-mesenchymal transition (EMT), with elevated 
Sox2 levels in PDACs linked to poor PDAC patient prognosis31,32. Poorly differentiated, 
mesenchymal-like PDACs (QM-PDACs) also express higher levels and activity of the Hippo 
transcription factor Yes-associated protein 1 (YAP), and YAP directly induces SOX2 and an 
EMT20,33 37. These findings suggest QM-PDACs may arise through elevated YAP and SOX2 
activity. YAP is exquisitely sensitive to mechanical stimuli such that cells interacting with a stiff 
ECM activate more ROCK to increase nuclear YAP and induce YAP-dependent gene 
expression38,39. Importantly, PDACs are mechanically-activated tumors composed of a 
progressively stiffened ECM and high interstitial pressure2,8,11. Thus, the elevated tissue 
mechanics mediated by the stiffened tissue stroma and high interstitial pressure could eventually 
activate YAP to drive tumor aggression and induce an EMT. Yet, many oncogenes also induce 
tissue tension by increasing Rock-dependent contractility. Indeed, the majority of PDACs have 
activated Kras, and Kras activity, per se, increases ROCK to drive cell contractility which, in 
turn, induces ECM remodeling and stiffening to drive integrin-dependent mechanosignaling and 
malignant transformation40,4142. It is therefore also equally plausible that the genotype of the 
pancreatic tumor epithelium additionally elevates tissue tension to drive tumor progression. 
Here, we examined human pancreatic tumor tissue of differing grades and survival, and 
exploited a series of PDAC GEMMs to explore the relationship between tumor genotype, 
stromal-epithelial interactions and tissue tension in PDAC progression and aggression.  
 
Results 
Human PDAC aggression is characterized by low epithelial TGF  signaling and high 
myosin activity 
PDACs are fibrotic, and contain abundant fibrillar collagen1.Yet, recent findings suggest 
collagen abundance may associate with better, not worse, patient prognosis and that high 
collagen content correlates with a more differentiated PDAC  phenotype43 45. Nevertheless, high 
fibrillar collagen has repeatedly been implicated in PDAC aggression and treatment resistance46. 
To address this discrepancy, we constructed a gene list of major fibrillar collagens 
(Supplementary Table 1) and used this signature to interrogate a publically-available NCBI GEO 
agilent gene expression data set (GSE21501) consisting of 67 PDAC patients between the ages 
of 40 and 65. We could find no statistical differences in the combined expression levels of the 
major fibrillar collagens and patient survival. However, when we created a median centroid 
value representing an average high versus low Col1 2, Col2 1 and Col4 1 combined 
expression score for each patient and graphed each of the groups over time, a Cox-Mantel Log-
rank analysis revealed that patients with high levels of these fibrillar collagens had a reduced 
overall survival, as illustrated by Kaplan-Meier survival curves (log rank p 0.04; Fig. 1a). These 
data suggest elevated gene expression of specific fibrillar collagens can predict poorer patient 
outcome. 
 Collagens are subjected to a plethora of posttranslational modifications that can modify 
their organization and mechanical properties. Therefore, to more directly investigate the 
relationship between fibrillar collagens and PDAC tumor phenotype, we secured PDAC tissue 
arrays from US Biomax representing a total of 68 patients between the ages of 23 and 78 with 
well (n=19), moderately (n=23) and poorly differentiated (n=26) tumors. A UCSF pathologist 
confirmed tumor grade using H&E stained sections. Thereafter, serial sections were stained for 
total collagen using Massons Trichrome and assessed for fibrillar collagen levels, organization 
and diameter using polarized imaging of Picrosirius Red (PR) stained tissue and second-
harmonic generation (SHG). A superficial analysis of the H&E and trichrome stained images 
implied that the poorly differentiated PDACs contained reduced stroma and total collagen, 
consistent with the reduced level of alpha smooth muscle actin ( SMA) positive cells we also 
detected (Fig. 1b )11,47. Nevertheless, quantification of PR stained, polarized images revealed 
there was a modest, albeit non-significant, increase in total fibrillar collagen in the least 
differentiated tumors (Fig. 1 b ). Furthermore, quantitative analysis of SHG images revealed 
that the collagen fiber diameter was significantly thicker in the poorly differentiated PDACs, 
suggesting higher localized tissue tension. Indeed, additional analysis revealed there was a 
significant and progressive increase in levels of pMLC2, reflecting higher mechanosignaling in 
the epithelium of the moderately and poorly differentiated tumors (Fig. 1b, ). Moreover, upon 
further examination, we established an inverse relationship between levels of nuclear pSmad and 
PDAC differentiation (Fig. 1b, ).     
 To further interrogate the relationship between fibrillar collagen phenotype, 
mechanosignaling and patient survival, we secured a set of tissues from a 57 patient PDAC 
cohort representing patients with a median short survival of less than 10 months (n=29) as 
compared to a median long-term survival of over 24 months (n=28) 48. Consistent with prior 
findings, Massons Trichrome stained tissue and polarized imaging of PR stained sections 
indicated there was no consistent relationship between total and fibrillar collagen or SMA 
positive stained cells in the tissues from patients with the short versus the longer survival (Fig. 
1c ). However and importantly, we again found that fiber diameter was significantly thicker in 
those patients with the shortest survival, as revealed by SGH. We also noted that the PDAC 
tissues from patients with the shortest survival contained the highest amount of epithelial 
pMLC2, suggesting they had elevated mechanosignaling and tissue tension (Fig. 1c ). 
Moreover, once again, the epithelium in the PDAC tissue excised from the patients with the 
shortest survival also had low to negligible detecta ). These findings 
indicate collagen organization and tissue tension, and not collagen abundance, are more robust 
indicators of PDAC aggression. The data also suggest reduced TGF  signaling in the PDAC 
epithelium may alter stromal-epithelial interactions to drive tumor aggression. 
 
Tumor genotype tunes epithelial tension to regulate the fibrotic phenotype  
To explore the relationship between TGF  signaling and tissue mechanics, the fibrotic 
phenotype and tumor aggression we exploited available PDAC GEMMs. We used a GEMM in 
which mutant Kras was conditionally expressed in the pancreatic epithelial cells (KrasLSL-G12D/+; 
Ptf1 -Cre; KC)49 either alone or in combination with mice heterozygous for mutant P53 
(KrasLSL-G12D/+;TrP53R172H/+; Pdx1-Cre; KPC), lacking one allele of P53 (KrasLSL-
G12D/+;TrP53flox/wt; Ptf1 ; KP- -C) or those lacking one allele of the TGF  receptor II 
(KrasLSL-G12D/+;Tgfbr2flox/wt; Ptf1a-Cre; KTC). As has been previously reported, by 20 weeks 
Kras mice had progressed to PanIN lesions, whereas both the KPC and KTC mice developed 
frank PDACs23,24. Coincident with tumor formation, the pancreatic tissue of both the KPC and 
KTC mice was highly fibrotic, as indicated by abundant quantities of total and fibrillar collagen 
(not shown). Mass spectroscopy proteomics analysis confirmed that many of the fibrillar 
collagens in the KTC and KPC mice were present at similar levels (Supplementary Table 2) and 
immunofluorescence staining revealed that both mouse GEMM PDACs had similar levels 
collagen III and numbers of SMA and FAP positive cells throughout their stroma 
(Supplementary Fig. 2a). Gli-1, which regulates PDAC fibrosis, was also abundantly and 
uniformly expressed equally in the stroma in both PDAC models (Supplementary Fig. 2a). 
Nevertheless, and in agreement with our clinical findings, PR and SHG imaging revealed that the 
PDACs in the KTC mice had significantly thicker collagen bundles that were particularly evident 
in the region surrounding the tumor epithelium, which atomic force microscopy (AFM) indicated 
was significantly stiffer than the stroma surrounding the KPC tumor epithelium (Fig. 2a, a ). 
Upon further scrutiny, we noted that the altered fibrillar collagen phenotype and the elevated 
stromal stiffness in the KTC PDACs was accompanied by a significant increase in levels of 
matricellular proteins including tenascin C, fibronectin and collagen XIIA (Fig. 2a, b). The 
epithelium of the KTC PDACs also had higher mechanosignaling, as revealed by more activated 
1 integrin and p397FAK, with greater nuclear levels of the mechano-activated transcription 
factor YAP (Fig. 2a). These findings indicate that loss of pancreatic epithelial TGF  signaling 
induces a mechanically-activated, matricellular-enriched fibrotic phenotype. 
 Importantly and consistent with our clinical findings, we quantified more pMLC2 and 
pMyPT1 in the epithelium of the KTC PDACs, implicating loss of TGF  signaling in the 
elevated tissue mechanics (Fig. 2a). Indeed, traction force microscopy (TFM), which quantifies 
the contractility phenotype of individual cells, revealed that freshly isolated pancreatic KTC 
tumor cells and cultured pancreatic Kras tumor cells lacking Tgfbr2 expression were 
significantly more contractile (Fig ). Further studies confirmed this observation and 
showed the KTC tumor cells were able to induce more ROCK-dependent collagen gel 
contraction than isolated cancer cells f
). The KTC pancreatic tumor cells also drove more ROCK-dependent 
collagen gel remodeling and stiffening (Fig. 2 ), more 
ROCK-dependent fibrosis and tissue stiffening when injected into the pancreas of immune-
compromised mice, and activated more Yap as indicated by higher nuclear levels and increased 
CTGF expression (Fig.  and Supplementary Fig. 3c , c ). Not only were the pancreatic 
tumor cells able to directly promote ROCK-dependent tissue fibrosis, but the phenotype was 
independent of proliferation with the non-fibrotic KPC pancreatic tumor cells forming larger, not 
smaller, tumors than those generated by the control and ROCK-knockdown KTC tumor cells 
(Supplementary Fig. 3c ). Thus, although pancreatic transformation is universally 
accompanied by a progressive fibrosis and stiffening of the ECM, the nature of the fibrotic 
response and the mechano-phenotype of the cancer can be modified by the genotype of the 
tumor. In particular, loss of TGF  signaling in the epithelium can increase cancer cell 
contractility to "tune" the mechano-fibrotic phenotype of the malignant tissue. 
 
Loss of TGF  signaling activates a JAK/Stat3 contractility feed forward circuit to induce 
ECM remodeling and tissue stiffening  
G protein coupled receptor (GPCR)-mediated JAK activation not only stimulates Stat3 but 
activates ROCK and induces actomyosin-mediated cell contractility50 and GPCR activation can 
activate Yap39. Stat3 activity is frequently elevated in pancreatic tumors51,52 and KTC tumors 
express elevated cytokines. We therefore tested whether the matricellular fibrosis and elevated 
mechano-phenotype observed in the KTC mice could be mediated through elevated pancreatic 
epithelial GPCR-JAK-ROCK-Stat353. In keeping with this paradigm, we noted that pStat3 
staining was, indeed, significantly higher in the pancreatic epithelium of the KTC mice (Fig. 3a, 
), even in the eight week old PanINs where the amount of infiltrating immune cells is quite low 
(Supplementary Fig . Indeed, while both the stroma and the PDACs in the KPC and KTC 
mice stained positively for pStat3, coincident with an abundant immune infiltrate53, pStat3 was 
consistently higher in the KTC tumor pancreatic epithelium (Fig. 3a, a
abundant pStat3 in non-stimulated, pancreatic epithelial cells isolated from KTC tumors, 
whereas no activity was detected in either the newly isolated KPC and KC tumor cells (Fig. 3b). 
Moreover, the ability of the KTC tumor cells to contract collagen gels and to induce collagen 
remodeling was blocked by treatment with the JAK inhibitor Ruxolitinib (Fig. 3c, c , c
Supplementary Fig. 4b). We also noted that the 48 hour conditioned media from KTC tumor 
cells activated pStat3 in cultured KC cells , and stimulated KC cell contraction and 
collagen remodeling, suggesting KTC cells secrete cytokines capable of inducing GPCR-JAK-
ROCK-dependent contractility (Fig. 3  and Supplementary Fig. 4c). Importantly, a stiff 
ECM can enhance GPCR-dependent Stat3 activation, and we observed higher steady state 
epithelial pStat3 and quantified higher levels of secreted cytokines in the media of Kras 
pancreatic tumor cells plated on a stiff ECM (Fig Supplementary Fig. ). 
These findings not only identify epithelial JAK-ROCK-Stat3 signaling circuit as a candidate 
KTC tumor cell-specific contractility mechanism that could drive ECM remodeling and 
pancreatic fibrosis, they also imply that once stiffened, the rigid ECM will potentiate the activity 
of this pathway and would promote tumor aggression by activating mechano-activated pathways 
including Yap20.  
 
Tumor cell tension induces JAK-Stat3 signaling and matricellular fibrosis to accelerate 
Kras PDAC 
To directly test whether epithelial contractility, per se, could induce matricellular fibrosis and 
PDAC progression we crossed transgenic mice expressing Ptf1 -Cre with mice expressing a 
-dependent integrin clustering and 
promotes focal adhesion signaling to induce ROCK-dependent cell contractility in the pancreatic 
epithelium(Supplementary Fig. 5a) 40,54,55. Immunofluorescence staining for p397FAK confirmed 
elevated focal adhesion kinase activity in the pancreatic epithelium in the 1V737N mice, 
revealed higher epithelial contractility by increased pMLC2 and higher mechano-signaling by 
elevated nuclear Yap targets such as CTGF (Supplementary Fig. 5b, c). Increased ductal 
collagen was indicated by intense PR staining around the epithelium (Supplementary Fig. 5b) 
while SHG revealed thicker, denser collagens (not shown), and AFM indentation quantified a 
stiffened ECM surrounding the ductal epithelium (Supplementary Fig. 4b). The presence of 
pStat3 positive pancreatic epithelial cells in the 1V737N mice, even in the absence of any 
activating oncogene or pre-existing inflammation, confirmed that epithelial tension can enhance 
p Stat3 (Supplementary Fig. 5b), a finding that we verified in a mouse cohort treated with a FAK 
inhibitor by the loss of pStat3 together with reduced p397FAK, pMLC2 and matricellular fibrosis 
( . Consistently, pancreatic orthotopic tumors formed by KTC cells 
lacking FAK were less fibrotic, and the tumors were softer and lacked epithelial pStat3 (Fig. 
4e, e , e  b). 
 To directly assess the relationship between epithelial mechanosignaling and PDAC 
development, we bred Ptf1 -  mice with KC mice and monitored the 
animals for development of matricellular fibrosis, elevated tissue mechanics, pStat3 signaling 
and tumor formation (Fig. 4a). As early as 5 weeks of age, the pancreatic epithelium in the KC 
mice expressing the 1V737N transgene had high p397FAK and pMLC2 activity, and the amount 
and distribution of deposited collagen and ECM stiffening was highest around the ductal 
epithelium (Fig. 4 ), and markedly similar to what we documented in the developing KTC 
lesions (compare SHG in Fig. 2a to PR in Fig. 4b). Moreover, consistent with the matricellular 
fibrosis observed in the patient samples lacking pSmad and the KTC lesions, we also detected 
abundant tenascin and higher levels of epithelial pStat3 in the KC/ 1V737N mice (Fig. 4b, b ). 
This was accompanied by a significant increase in infiltrating CD45 immune cells 
(Supplementary Fig. 7c) and CD68 macrophages (Fig. 4b, ), which FACS analysis suggested 
were tumor promoting (Supplementary Fig. 7c). Indeed, cytokine array analysis demonstrated 
that the KC/ 1V737N mouse pancreas expressed significantly higher levels of pro-inflammatory 
factors C5 and IL1 (Supplementary Fig. 7d, ). Finally and importantly, histological analysis 
confirmed that KC/ 1V737N mice developed chronic pancreatitis as early as 3 months of age 
(Fig. 4c). Alcian blue staining of 3 month old KC/V737N mouse pancreatic tissue revealed that 
they had progressed to advanced, high grade PanINs that were evenly distributed throughout the 
tissue and H&E showed that 38% of the animals developed frank PDAC by 5-8 months of age, 
with accompanying physiological trauma including loss of body weight (Fig. 4c, d). These 
results reveal that tumor cells with elevated mechano-signaling are more contractile and, by 
virtue of their ability to stiffen the ECM, induce matricellular fibrosis, activate tension-regulated 
genes and stimulate an immune response, can promote pancreatic transformation. 
 
Stat3 induces tissue fibrosis to accelerate Kras-induced PDAC  
We next explored the relationship between activated Stat3, cell contractility and pancreatic 
matricellular-enriched fibrosis in PDAC. KC mice were crossed into mice expressing one allele 
of a constitutively active Stat3 (Stat3C, Fig. 5a)56. We first noted that Stat3C mice contained 
numerous cells within the pancreas that stained positively for activated Stat3 (Supplementary 
 and that the level of pStat3 increased dramatically following expression of an 
activated Kras (Fig. 5b ). We also quantified higher numbers of CD45 immune cells and 
CD68 macrophages within the Stat3C pancreatic tissues (Supp  and that 
these increased substantially with Kras activation, consistent with induction of a pro-
inflammatory phenotype (Fig. 5b ). Indeed, the pancreatic tissues of the Stat3C/Kras mice 
showed marked pancreatitis that developed into frank PDAC, which compromised the survival 
of the mice (Fig. 5c). Consistent with a link between JAK/Stat3 activity and ROCK activity, 
immunofluorescence staining revealed that, while tumors were stiffer and pMLC2 was quite high 
in the KC/Stat3C mice, pMLC2 levels were already elevated in the pancreatic tissues of the 
Stat3C mice, even in the absence of Kras (Fig. 5b, , d ). 
Polarized light imaging of PR stained tissue revealed that the pancreas of the Stat3C mice 
already contained abundant mature type I collagen ( ). Indeed, we were 
able to detect elevated p397FAK throughout the pancreas of the Stat3C mice (Supplementary Fig. 
).  These findings not only demonstrate that there are links between pStat3 and tissue 
inflammation, but they also suggest that pStat3 induces ROCK-dependent ECM remodeling and 
stiffening to drive matricellular fibrosis and mechanosignaling in PDAC.  
 
Stat3 enhances epithelial contractility to induce PDAC matricellular fibrosis and tumor 
aggression to compromise patient survival 
To establish a causal relationship between pStat3, tissue mechanics and PDAC development, we 
crossed mice expressing Kras (KrasLSL-G12D/+) with mice homozygous for loss of both of the TGF 
receptor 2 alleles (Tgfbr2flox/flox, which exhibit an accelerated matricellular fibrotic phenotype 
and PDAC development, Supplementary Fig. 8a, b) and Stat3 both in the pancreatic epithelium 
(Stat3flox/flox, Ptf1a-Cre) to create KTC KO/Stat3 KO mice (Fig. 5e)23,57. Immunostaining 
this was accompanied by reduced CD68 tissue infiltration, consistent with decreased 
reduction in epithelial p397FAK, pMLC2 and nuclear Yap levels and activity as indicated by 
d Supplementary Fig.  9b). Also, pancreatic tissues with 
deleted epithelial Stat3 presented with a striking reduction in matricellular-rich fibrosis and ECM 
stiffness, along with increased survival (Fig. g, h). Direct links between matricellular-rich 
fibrosis, mechanics and Stat3 were confirmed in a cohort of mice treated with the JAK inhibitor 
Ruxolitinib, which not only inhibited pStat3 activity but also reduced p397FAK, pMLC2, collagen 
fibrillogenesis and ECM stiffening (Supplementary Fig. 9 Yap activation (not 
shown). Moreover, in the absence of JAK-driven matricellular-rich fibrosis, mechanosignaling, 
Stat3-dependent inflammation and PDAC development were reduced (Supplementary Fig. 
e). Thus, tumor cell pStat3 not only stimulates inflammation, but increases epithelial cell tension 
and activates mechanosignaling to drive matricellular fibrosis and promote PDAC development 
and tumor aggression. Importantly and of clinical relevance, we detected elevated levels of 
tenascin and high nuclear YAP, SOX2 and pSTAT3 in the mesenchynmal-like, vimentin positive 
PDAC biopsies that we found lack pSMAD2, that were excised from the patients with the shorter 
medium survival (Fig. netic/epigenetic 
-activated and develop a 
unique, matricellular-enriched stroma that contributes to their aggression through YAP and 
SOX2 activation (Fig. 6b). Patients lacking signaling may represent a unique cohort of 
PDACs towards which anti-stromal therapies should be judiciously applied. 
 
Discussion  
While PDACs present with inarguably elevated stromal fibrosis, recent findings suggest that 
collagen abundance may associate with better patient prognosis, with high collagen content 
correlating with a well-differentiated PDAC phenotype44,58. Nevertheless, elevated fibrillar 
collagen has repeatedly been implicated in both PDAC aggression and treatment resistance43. To 
address these contradictory perspectives, we examined the relationship between tumor genotype, 
tissue tension, and fibrosis composition and architecture in PDAC progression and aggression. 
Using a series of well-characterized GEMMs, we identified a unique matricellular-stromal 
signature that associates with PDAC genotypes that elevate pancreatic cell contractility and 
tumor aggression. This coordination of genetically-induced tumor cell contractility and 
matricellular-enriched fibrosis "tunes" PDAC tissue tension and ultimately activates Yap to 
promote tumor aggression. This interplay suggests that bulk collagen content is a poor surrogate 
for the multifacted contributions of PDAC fibrosis to cancer aggression. Specifically, 
genetically-elevated epithelial tension promoted Yap activation and tumor aggression by 
stimulating Stat3-mediated ECM remodeling and stiffening of the stroma surrounding the 
developing pancreatic lesions. Consistently, ectopically-increasing epithelial mechanosignaling 
induced a matricellular-rich fibrosis and stiffened the stroma adjacent to the pancreatic 
epithelium, and activated Yap and Stat3 to induce inflammation and accelerate pancreatic 
transformation and induce aggression. Mechanistically, genetically-increasing epithelial Stat3 
activity amplified epithelial tension to drive a matricellular-enriched stiffened phenotype and 
accelerate malignancy, whereas genetic-ablation of epithelial Stat3 reduced epithelial tension, 
diminished fibrosis and tempered tumor aggression. Our findings provide the first direct 
evidence that PDAC genotype calibrates tumor cell contractility to modulate the fibrotic 
phenotype of the tissue and by so doing modifies the pathology of the resultant cancer.  
 By exploiting a series of GEMMs, we were able to elucidate that the matricellular-
enriched fibrotic phenotype we clinically-linked to the increased tumor cell contractility and loss 
50. 
W
tumor epithelium exhibits a significantly elevated actomyosin-mediated tension that is stimulated 
by an autocrine, cytokine-induced JAK-ROCK-Stat3 mechanosignaling circuit which conditions, 
remodels and stiffens the ECM adjacent to the developing pancreatic lesions to further amplify 
pStat3 signaling and drive tumor progression. Our data showed that this feed forward circuit 
potentiates a Stat3-mediated epithelial pro-inflammatory phenotype and promotes FAK-
dependent Yap activation to drive tumor progression and aggression. Indeed, while inflammation 
and fibrosis can both independently promote pancreatic transformation and aggression, our 
findings are the first to describe a novel mechanism whereby Stat3-mediated tumor aggression is 
able to directly induce epithelial contractility to drive ECM stiffening and modify the fibrotic 
response51,52. Of clinical relevance, we demonstrated that nuclear YAP and YAP targets are 
progressively increased as a function of PDAC transformation and tissue fibrosis, and we 
showed that this phenotype is significantly accelerated by Stat3-driven, contractility-mediated 
tissue stiffening (compare Fig. 2a to Fig. 5f). Our clinical findings revealed that the least 
differentiated PDACs and the PDACs developing in patients with the shortest survival that 
ithelial contractility and expressed elevated 
pSTAT3, YAP and the YAP target SOX2, all transcriptional regulators that have been implicated 
in tumor aggression and epithelial-to-mesenchymal transition31 34.  Indeed, these same YAP and 
SOX2 expressing tumors also stained strongly for markers of a mesenchymal-like phenotype 
including vimentin and tenascin C (Fig. 59 61. Given that YAP signaling can drive Kras-
independent PDAC growth and survival, these findings imply that fibrotic PDAC tumors may 
naturally evolve towards Kras independence and that this phenotype will be potentiated by 
need to be taken into consideration when designing treatment strategies to treat pancreatic cancer 
patients with drugs such as next generation Ras inhibitors or anti stromal therapies20,33. Such 
results may also provide a rationale for the failures of classic anti-stromal therapies which do not 
target epithelial-driven fibrosis (NCT01472198)10 12. In this regard, our data present one 
plausible explanation for the mixed response of PDAC cancer patients to anti-stromal therapies, 
and suggest that FAK and JAK inhibitors, which target both stromal and epithelial-driven 
fibrosis, and both of which reduced YAP and tenascin induction, may comprise more efficacious 
therapeutic options.  
While the magnitude of the fibrotic response derived from each distinct PDAC genotype 
initially varied, all of the PDAC models used in our studies eventually trended towards the 
development of fibrosis, albeit with different end stage fibrotic phenotypes. Thus, although the 
KPC model demonstrated muted epithelial contractility and initial lower levels of tissue tension 
compared to the highly fibrotic KTC model, KPC tumor progression was eventually 
accompanied by an activated stroma that developed into a robust fibrotic response, a progressive 
stiffening of the ECM and accumulation of high nuclear Yap, in at least a subset of pancreatic 
tumor cells. The data suggest a primary tumor evolution towards the mesenchymal-like features 
often observed in patients presenting with recurrent PDAC. In fact, mesenchymal-like PDACs 
express higher levels and activity of YAP which, in turn, feeds back to further promote a pro-
fibrotic, mesenchymal-like tumor phenotype both directly and via stimulation of SOX2. Our 
results thereby suggest that patients presenting with high grade PDAC will exhibit a highly 
mechanoresponsive epithelial phenotype early in PDAC progression while patients presenting 
with low grade disease will exhibit a gradual elevation of tissue fibrosis leading to eventual YAP 
activation in the epithelial and stromal compartments by end state PDAC, as well as in recurring 
tumors. Given that YAP drives an EMT and mesenchymal-like tumor cells exhibit stromally-
independent survival and growth, stromal ablation in PDAC patients with pre-existing disease or 
aggressive genotypes would predictably fail. Thus, our results may explain why ablation of 
fibrosis does not always block PDAC progression and, in some instances, actually promotes 
tumor aggression and why recent clinical trials using anti-stromal fibrotic agents failed to 
provide benefit to patients. Indeed, given that Kras-dependency is strongly linked to epithelial 
status 62 which diminishes with EMT and that YAP drives PDAC aggression independently of 
Kras by activating an EMT-like program33, most PDAC patients may similarly exhibit resistance 
to targeted therapies including receptor tyrosine kinases and their downstream effectors and new 
generation Ras therapies. Importantly, our studies suggest that novel treatment modalities 
holistically targeting both epithelial and stromal-driven fibrosis, cellular contractility and YAP 
activity, such as combinatory FAK/JAK inhibitor cocktails, will likely prove to be more 
efficacious therapeutic strategy with which to treat PDAC patients. These observations are 
consistent with previous implications of YAP in mechanotrasduction38 and provide a mechanistic 
rationale with which to design future therapeutic interventions for patients since the highly 
contractile cell phenotype driven by Stat3 signaling exhibits high YAP activity which is 
reminiscent of the quasi-mesenchymal-like and recurrent patient PDAC phenotype. Taken 
together with previous findings, our work would then suggest that the use of FAK inhibitors 
should provide therapeutic benefit for the quasi-mesenchymal and Kras-independent PDAC 
subtypes with elevated YAP, block progression and recurrence of low grade PDAC, and slow the 
progression of high grade PDAC. 
 
Experimental procedures  
Human samples 
Formalin-fixed, paraffin-embedded human PDAC tissue sections, lacking any patient-identifying 
information, were commercially purchased from US Biomax (PA961a) or obtained from cohort 
of patients based on long and short survival 48.  
Mice studies 
All mice were maintained in accordance with University of California Institutional Animal Care 
and Use Committee guidelines under protocol number AN105326-01D. Transgenic mouse 
strains, KrasLSL-G12D/+;Ptf1a-Cre (KC; 49), KrasLSL-G12D/+;TGFbR2flox/wt or flox/flox;Ptf1a-Cre (KTC; 
23); KrasLSL-G12D/+;TrP53R172H/+; Pdx1-Cre (KPC; 24, LSL- 54), Stat3flox/flox 57 and 
constitutively active Stat3C 56 were described previously. Mice were interbred and maintained in 
mixed background. Aged matched littermates not expressing Cre as well as Ptf1a-Cre and Pdx1-
Cre mice were used as controls.  
For FAK inhibition studies, Ptf1a-Cre/ 1V737N mice were treated with FAK inhibitor PND-
1186  at 0.5 mg/ml in 5% sucrose in the drinking water, control mice were provided 5% sucrose 
as drinking water (n = 5 per group). Treatment started at 3 weeks and mice were killed after 3 
weeks. For JAK inhibition, KTC mice were treated with JAK inhibitor Ruxolitinib twice daily by 
oral gavage at 60 mg/kg body weight in 0.5% methylcellulose in water. Control mice were 
provided 0.5% methylcellulose in water (n = 5 per group). Treatment started at 3 weeks and mice 
were killed after 3 weeks. 
For orthotopic xenografts, 5x105 firefly luciferase-mApple expressing cells in Matrigel (BD 
Biosciences) were injected into the pancreas of 8-week old nude mice (Simonsen laboratory) (n 
= 5 per group) and tumor growth was monitored by weekly bioluminescent imaging.  
For bioluminescent imaging animals were injected intraperitoneally with 3 mg of D-Luciferin 
and imaged using IVIS spectrum imaging system. The living imaging 4.3 software was used for 
analysis of the images post acquisition.  
Histology  
Paraffin-embedded or Fresh frozen pancreatic tissues were analyzed by H&E, picrosirius red, 
 
LC-MS/MS and LC-SRM Proteomic analysis 
Proteomic analysis was performed in triplicate on 5 milligrams of fresh frozen KC, KPC, and 
KTC pancreatic tissues as previously described 63 Briefly, tissues were milled in liquid N2 
followed by sequential extraction of cellular proteins, soluble ECM proteins, and insoluble ECM 
proteins. Tryptic digests of all fractions were analyzed by both LC-MS/MS and LC-SRM mass 
spectrometry. Peptide Spectral Matches (PSMs) from LC-MS/MS was used for relative 
comparisons of protein abundances between samples. Additionally, Stable Isotope Labeled (SIL) 
peptides were used for absolute quantification of ECM proteins by LC-SRM.  
Atomic force microscopy measurements 
Atomic force microscopy and analysis were performed as previously described 64. 
Two-photon second harmonics microscopy and image analysis  
Two-photon imaging of pancreatic tissues and collagen gels was performed and quantified as 
previously described 65.  
Traction force microscopy  
Traction of pancreatic cells was measured as previously described 40,66. 
Three dimensional collagen contraction assay  
Collagen contraction assay was performed as previously described 50 
Polyacrylamide substrates 
Fibronectin conjugated polyacrylamide hydrogels were prepared as previously described 54.  
Cytokine antibody array.  
Cytokine levels were screened by using mouse cytokine antibody array according to the 
 instructions.  
Immunostaining and immunoblotting  
Immunofluorescence and immunoblotting analysis were performed as previously described 67. 
Antibodies used for immunofluorescence!and immunoblotting analysis are listed in the extended 
experimental procedures. 
Lentivirus-mediated shRNA knockdown 
Lentiviral shRNA targeting ROCK1 and FAK and nontargeting shRNA control were cloned in 
the pLKO vector. The TRC IDs for the shRNA used in the study are listed in the extended 
experimental procedures. 
Bioinformatics 
Patient expression data was pulled from publicly available dataset GSE21501 obtained from 
NCBI GEO. Following baseline normalization, expression values for Col1a2, Col2a1, and 
Col4a1 were used to create a median centroid value representing an average collagen expression 
score for each patient. These values were then divided into high and low expression based on 
median centroid value for the patient set and graphed as survival of each group over time. 
Kaplan Meier survival curves were analyzed by Cox Mantel Log-rank analysis. 
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Figure 1: Human PDAC aggression is characterized by low epithelial TGF  signaling and 
high myosin activity. 
(a) Kaplan-Meier of overall survival of PDAC patients from GSE21501 with patients divided 
into those with high and low collagen expression by normalized microarray analysis of collagen 
gene expression, log rank p=0.04, n=67. (b) Representative photomicrographs of H&E (top 
nd panel) stained PDAC tissue arrays from patients with well 
(n=19), moderately (n=23) or poorly differentiated (n=26) tumors. Scale bar, 100µm. 
Representative immunofluorescence images of pancreatic tissue described above stained for 
SMA (red, 3rd, panel), pMLC2 (red, 7th panel), pSMAD2 (red, 8th panel) and DAPI (blue). 
Scale bar, 75µm. Representative polarized light images of picrosirius red (PR) stained pancreatic 
tissue (as described above) revealing collagen fiber structure, orientation and distribution within 
the tissue stroma (4th panel). Scale bar, 50µm. Representative second harmonic generation (SHG) 
images of extracellular collagen architecture in the pancreatic tissue around the epithelial ductal 
region described above (5th panel) and SHG color-coded images revealing collagen fiber 
diameter (6th panel). Scale bar, 75µm.  Bar graphs quantifying the tissue images shown in the 
panels in b. (c) Representative photomicrographs of H&E 
(2nd panel) stained PDAC tissue arrays from PDAC patients cohort representing patients with a 
median short survival of 11-289 days (n=29) and median long survival of 1090-3298 days 
(n=28). Scale bar, 100µm. Representative immunofluorescence images of pancreatic tissue (as 
described above) stained for SMA (red, 3rd, panel), pMLC2 (red, 7th panel), pSMAD2 (red, 8th 
panel) and DAPI (blue). Scale bar, 75µm. Representative polarized light images of PR stained 
pancreatic tissue as described above revealing collagen fiber structure, orientation and 
distribution within the tissue stroma (4th panel). Scale bar, 50µm. Representative SHG images of 
extracellular collagen architecture in the pancreatic tissue around the epithelial ductal region 
described above (5th panel) and SHG color-coded images revealing collagen fiber diameter (6th 
panel). Scale bar, 75µm. Bar graphs quantifying the tissue images shown in the panels in c.  
(*p<0.05; **p<0.01, ***p<0.001, ****p< ). 
 
Figure 2: Tumor genotype tunes epithelial tension to regulate the fibrotic phenotype.  
(a) Representative SHG images of extracellular collagen architecture and distribution in the 
pancreatic tissue from 20 weeks old pancreatic tissue excised from mice expressing Kras (KC), 
Kras with one mutant allele of P53 (KPC) or Kras with heterozygous loss of Tgfr2 in the 
pancreatic epithelium (KTC) (1st panel). Scale bar, 75µm.Representative force maps measured 
using AFM indentation of the stiffness of the extracellular matrix surrounding the pancreatic 
ductal lesions developing in the 20 week old animals (1st panel insert). Representative 
immunofluorescence images of pancreatic tissue described above stained for Tenascin C (red, 2nd 
panel; scale bar, 75µm), pMLC2 (red, 3rd panel), 1integrin/pFAK (green/red, 4th panel), 
pMyPT1 (red, 5th panel), YAP (red, 6th panel) and DAPI (blue). Scale bar, 50µm.  Bar graphs 
quantifying the fibril thickness and distribution imaged by SHG around the developing 
pancreatic ductal lesions pf pancreatic tissue described above.  Bar graphs showing the 
distribution of the stiffness measurements of the extracellular matrix surrounding the normal and 
developing lesions (in tissue described above) as assessed by atomic force microscopy 
indentation. (b) Bar graphs quantifying the matrix protein concentration of Tenascin C, 
Fibronectin 1 and type 12A1 Collagen in tissue described above as measured by mass 
spectrometry. (c) Representative traction force maps measured on polyacrylamide gels (2300 Pa) 
for isolated KC, KPC and KTC pancreatic epithelial tumor cells.  Corresponding 
quantification of c. (d) Polarized light images of color-coded PR stained collagen gels incubated 
with KC, KPC or KTC pancreatic epithelial tumor cells or with KTC cells treated with vehicle or 
the ROCK inhibitor Y27632.  Bar graphs quantifying three dimensional collagen gel 
contraction as indicated by collagen gel area. Cultures were assayed after 24 hours. (e) 
Representative polarized light images of PR stained pancreatic tissue excised from nude mice 3 
weeks after injection with KC, KPC, and KTC pancreatic tumor cells expressing either a control 
shRNA or an shRNA to ROCK (top panel). Scale bar, 75µm. Representative 
immunofluorescence images of pancreatic tissue described above stained for YAP (red) and 
DAPI (blue). Scale bar, 50µm (bottom panel).  Bar graph quantifying the stiffness of the 
pancreatic tissue shown above in e using AFM indentation. ( ) Graphs quantifying the total 
level of fibrillar collagen measured in the pancreatic tissue shown in e. For in vitro bar graphs, 
results are the mean +/- SEM of at least 3 independent experiments. For in vivo experiments, 
N=5 mice per group. (*p<0.05; **p<0.01, ***p<0.001, ****p<
significant). 
 
Figure 3: Loss of TGF  signaling activates a JAK/Stat3 contractility feed forward circuit to 
induce ECM remodeling and tissue stiffening.  
(a) Representative immunofluorescence images of pancreatic tissue excised from 20 week old 
KC, KPC and KTC mice stained for pStat3 (red) and DAPI (blue). Scale bar, 50µm.  Bar 
graphs quantifying the level of stromal versus epithelial p-Stat3 in the tissues stained in a. (b) 
Representative immunofluorescence images of isolated KC, KPC and KTC tumor cells stained 
for pStat3 (red) and DAPI (blue). Scale bar, 25µm. (c) Representative polarized light images of 
PR stained color-coded fibrillar collagen in three dimensional collagen gels incubated with KTC 
tumor cells for 24 hours either with vehicle or the JAK inhibitor Ruxolitinib. (c ) Bar graphs 
showing amount of collagen contraction as measured by total collagen gel area. (c ) Bar graphs 
showing mean collagen fiber diameter measured in the three dimensional collagen gels shown in 
c. (d.) Representative immunoblot of Stat3 activation (pStat3) as a function of time following 
exposure to the conditioned media (CM) obtained from KTC tumor cells.  Line graph 
quantifying the relative level of pStat3 measured in the KC cells shown above in d. (e) 
Representative polarized light images of PR stained, color-coded fibrillar collagen in three-
dimensional collagen gels incubated with KC tumor cells treated with vehicle or the conditioned 
media from 48 hour cultured KTC tumor cells. (e ) Bar graphs showing amount of collagen 
contraction as measured by total collagen gel area in . (e ) Bar graphs showing mean collagen 
fiber diameter measured in the three dimensional collagen gels shown in e. (f) Representative 
immunoblot of total (Stat3) and activated Stat3 (pStat3) levels in KC tumor cells cultured on soft 
or stiff polyacrylamide substrates. Results are normalized to total Stat3 and Gapdh.  bar 
graphs showing quantification of f. (g) Quantification of cytokine protein expression measured in 
the conditioned media of KC cells cultured on soft or soft polyacrylamide substrates. For in vitro 
bar graphs, results are the mean +/- SEM of at least 3 independent experiments. For in vivo 
experiments, N=5 mice per group. (*p<0.05; **p<0.01, ***p<0.001, ****p<
denotes not significant). 
 
Figure 4: Stat3 induces tissue fibrosis to accelerate Kras-induced PDAC.  
(a) Cartoon of mouse manipulations used to study the impact of increasing pancreatic epithelial 
cell mechanosignaling using 1V737N on Kras-induced pancreatic malignancy. (b) 
Representative immunofluorescence images of pancreatic tissues excised from 3 month old KC 
and KC/ 1V737N mice stained for p397FAK (top panel; red) and p-MLC2 (2nd panel; red), 
Tenascin C (5th panel, red), YAP (6th panel, red), pStat3 (7th panel; red), scale bar, 50 µm, CD68 
(8th panel; red), and DAPI (blue). Scale bar, 100µm. (3rd panel) Representative polarized light 
images of collagen fibers revealed by PR staining of pancreatic tissue described above. Scale bar, 
75µm. b. (4th panel) Representative force maps of ECM stiffness measured using atomic force 
microscopy indentation in pancreatic tissue described above. (b') Bar graphs quantifying the 
tissue images shown in the panels in b. (c) Representative alcian blue images of transformed 
ducts and representative H&E images of pancreatic tissue and tumor morphology. Scale bar, 
100µm.  corresponding quantification of c. (d) Bar graphs showing mouse body weight at 
study termination. (e) (top) Representative polarized light images of collagen fibers revealed by 
PR staining of pancreatic tissues in nude mice injected with KTC tumor cells expressing either a 
control shRNA or a FAK shRNA. Scale bar, 75 µm (top panel). Representative 
immunofluorescence confocal images of pancreatic tissue described above in e stained for pStat3 
(red, 2nd panel; scale bar, 25 µm), YAP (red 3rd panel; scale bar, 75 µm) and DAPI (blue).  
Bar graphs quantifying total collagen fibril content of picrosirius stained tissue shown in e. ( ) 
Bar graphs quantifying average elastic modulus (Pa) measured by atomic force microscopy of 
pancreatic tissue shown in e. For in vivo experiments, N=5 mice per group. (*p<0.05; **p<0.01, 
***p<0.001, ****p< ). 
 
Figure 5: Stat3 induces tissue fibrosis to accelerate Kras-induced PDAC. 
(a) Cartoon depicting the mouse crosses used for the activated Stat3C manipulations. (b) 
Representative immunofluorescence images of pancreatic tissues excised from 5 week old KC 
and KC/Stat3C mice stained for pStat3 (top panel; red), scale bar, 75 µm, p397FAK (2nd panel; 
red) and pMLC2 (3rd panel; red), Scale bar, 50 µm, CD68 (5th panel; red), and DAPI (blue). 
Scale bar, 100µm. b. (4th panel) Representative polarized light images of collagen fibers revealed 
by PR staining of pancreatic tissue described above. Scale bar, 75µm. b. (7th panel) 
Representative phase contrast images of H&E stained pancreatic tissue as described above. Scale 
bar, 100µm. b' Bar graphs quantifying the tissue images shown in the panels in b. (c) Kaplan-
Meier graph showing survival of KC, Stat3C, and KC/Stat3C mice. (d) Quantification of ECM 
stiffness measured by atomic force microscopy in pancreatic tissue shown in b. (e) Cartoon 
depicting the mouse crosses used for the Stat3 knock studies. (f) Representative 
immunofluorescence  images  of  pancreatic  tissues  excised from 5 week old  5  week  old 
homozygous KTC (KTC KO) (Control) and KTC/Stat3 KO mice (Stat3 KO) stained for pStat3 
(top panel; red), scale bar, 75 µm, p-397FAK (2nd panel; red) and p-MLC2 (3rd panel; red), 
scale bar, 50 µm, Tenascin (5th panel; red), CD68 (6th panel; red), scale bar, 100µm, Y A P 
( 7 t h  p an e l ;  r ed )  s ca l e  b a r ,  50µ m,  and DAPI (blue). ( f )  (4th panel) Representative 
polarized light images of collagen fibers revealed by PR staining of pancreatic tissue described 
above. Scale bar, 75µm. ( f )  (8th panel) Representative phase contrast images of H&E 
stained pancreatic tissue as described above. Scale bar, 100µ m. f ' Bar graphs quantifying 
the tissue images shown in the panels in f. (g) Kaplan-Meier graph  showing  survival  of  KTC 
and KTC/Stat3 KO  mice. (h)  Quantification of ECM stiffness measured by atomic force 
microscopy in pancreatic tissue shown in f. For in vivo experiments, N=5 mice per group. 
(*p<0.05; **p<0.01, ***p<0.001, ****p< ). 
 
Figure 6: Stat3 enhances epithelial contractility to induce PDAC matricellular fibrosis and 
tumor aggression to compromise patient survival.!
(a) Representative photomicrographs of H&E from PDAC patients cohort representing patients 
with a median short survival of 11-289 days (n=29) and median long survival of 1090-3298 days 
(n=28) (top panel). Scale bar, 100µm. Representative SHG images of extracellular collagen 
architecture in the pancreatic tissue around the epithelial ductal region in tissue described above 
(2nd panel). Scale bar, 75µm. Representative immunofluorescence images of pancreatic tissue 
described above stained for Tenascin C (red, 3rd panel), pSMAD2 (red, 4th, panel), pStat3 (red, 
5th panel), YAP (red, 6th panel), Sox2 (red, 7th panel), Vimentin (red, 8th panel) and DAPI (blue). 
Scale bar, 75µm.  Bar graphs quantifying the tissue images shown in the panels in a. (b) 
Cartoon depicting the epithelial JAK-ROCK-Stat3-YAP feed forward circuit and its potentiation 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental experimental procedures 
Cell culture and establishment of primary pancreatic cell lines  
Establishment of primary pancreatic tumor cells was performed as described previously (Aguirre 
et al., 2003). Cells were maintained in RPMI-1640 medium containing 10% FBS (Clontech). All 
experiments were performed within eight passages to avoid possible gross genomic changes 
during long-term in vitro culture. Derivative cells were transduced in vitro with a lentiviral 
vector-encoding firefly Luciferase and mApple fluorescent protein for combined bioluminescent 
imaging and flow sorting. To ensure that all cell lines expressed similar levels of luciferase, 
mApple expressing cells were flow sorted prior to injection into animals.  
Lentiviral shRNA constructs 
The clone IDs for shRNA are as follows: sh-ROCK1(TRCN0000022903), sh-FAK 
(TRCN0000023485) and eEGFP as a non specific control cloned into the lentiviral pLKO.1 puro 
vector (Sigma-Aldrich).  
Preparation of luciferase-mApple Virus-Infected Cells 
Lentivirus infection was performed with lentiviral vector for 
combined flow sorting and in vivo imaging. This was constructed from the pLKO.1 puro vector 
by inserting an in-frame fusion of mApple with the human codon optimized firefly luciferase 
promoter. This cassette, followed by a WPRE element was inserted in place of the U6 cppt 
mPGK puro elements in pLKO.1 puro (from claI to kpnI sites).  
Quantitative real-time PCR  
RNA was extracted using trizol/chloroform isolation followed by Ambion mirVana kit 
(AM1560). Total RNA was reverse-transcribed using random primers (Amersham Biosciences), 
-actin primers were used to control for cDNA concentration in a separate PCR reactions for 
each sample. LightCycler Fast Start DNA Master SYBR Green Mix (Roche) was added to each 
performed on a eppendorf realplex2 mastercycler using the real-time primers provided, 
according to instructions. Ct values were converted to fold expression changes (2  values) 
-actin. 





Weighed tumors were minced and allowed to digest in a mixture of 1mg/ml of collagenase P 
(Roche 11213857001), 0.1 mg/ml Collagenase I (Sigma, C0130), 0.1 mg/ml Dispase II (Roche, 
04942078001) and DNase (5MU/ml, Calbiochem, 260913) in DMEM media at 37°C for 30 min. 
The tissue lysate was filtered through a 40 µm mesh prior to immunostaining. The resulting 
single-cell suspension was stained with fixable viability dye eFluor 780, anti-CD45-APC-Cy7 
(103115), anti-CD11b-FITC (101205) and anti-Ly6/C-PE (128007) (all from BioLegend). The 
percentage of positive cells were analyzed by FlowJo and gated on CD45 positivity. Unstained, 
live/dead only, and single stain served as control. Doublets were gated out using forward-scatter 
width/height and sidewardscatter width/height event characteristics. 
Antibodies and reagents 
Antibodies were as follows: a-SMA (Sigma-Aldrich C6198), GLi-1 (Thermo Scientific PA5-
32206), LOX (Imgenex IMG-6442A), YAP (Cell signaling 4912) 1integrin (EMD Millipore 
MABT409), pY397-FAK (Invitrogen 44625), total FAK (BD Biosciences 610088), ROCK (Cell 
Signaling C8F7), p-MLC2 (Cell Signaling 3671), p-MyPT1 (Millipore ABS45), p-Stat3 (Cell 
Signaling 9145), total Stat3 (Cell Signaling 9132), GAPDH (Cell Signaling 2118), CD45 (BD 
Biosciences 550539), CD68 (Thermo Scientific Ab-3), Alexa Fluor-conjugated goat secondary 
anti mouse IgG and anti rabbit IgG antibodies (Invitrogen A11012 and A11005) and HRP-
conjugated rabbit secondary antibody (GE health care life sciences NA934VS). 
  
Gene Sequence 
CTGF -GTGAGTCCTTCCAAAGCAGC-  
R -TAGTTGGGTCTGGGCCAAAT-  
-actin -GTGGGCCGCCCTAGGCACCA-  
-CGGTTGGCCTTAGGGTTCAGGG-  
Supplementary Figure Legends 
Figure S1.  
(a) Representative second harmonic generation (SHG) images of extracellular collagen 
architecture and distribution in the pancreatic tissue from 8 week old pancreatic tissue excised 
from mice expressing Kras (KC), Kras with one mutant allele of P53 (KPC) or Kras with 
heterozygous loss of the Tgfbr2 receptor in the pancreatic epithelium (KTC) (1st panel). Scale 
bar, 75µm. Representative force maps measured using atomic force microscopy (AFM) 
indentation of the stiffness of the extracellular matrix surrounding the pancreatic ductal lesions 
developing in the 8 week old animals (1st panel insert). Representative immunofluorescence 
images of pancreatic tissue described above stained for pMLC2 (red, 2nd panel), 
ß1integrin/p397FAK (green/red, 3rd panel), pMyPT1 (red, 4th panel), YAP (red, 5th panel) and 
DAPI (blue). Scale bar, 50µm. ( ). Bar graphs quantifying the fibril thickness and distribution 
imaged by SHG around the developing pancreatic ductal lesions of pancreatic tissue described 
above. (  Bar graphs showing the distribution of the stiffness of the extracellular matrix 
surrounding the normal and developing lesions in tissue described above as measured by AFM 
indentation. (b) Bar graphs quantifying the tissue images shown in the panels in a and in Fig. 1a. 
Figure S2.  
(a) Representative immunofluorescence images of pancreatic tissues stained for Collagen 3 
(green, 1st panel), FAP (green, 2nd panel), Gli1 (green, 3rd th panel) and 
DAPI (blue) from 20 weeks old tissue excised from mice expressing Kras with one mutant allele 
of P53 (KPC) and Kras with heterozygous loss of the Tgfbr2 in the pancreatic epithelium (KTC). 
(b) Representative immunofluorescence images of pancreatic tissues stained 
for ß1integrin/p397FAK (green/red, top panel), YAP (red, bottom panel) and DAPI (blue) from 20 
weeks old tissue excised from mice expressing Kras with heterozygous loss of the P53 (KP-
Ptf1a-C) and Kras with heterozygous loss of the Tgfbr2 in the pancreatic epithelium (KTC). 
in vivo experiments, N=5 mice per group. *p<0.05; **p<0.01, 
***p<0.001, ****p<  
Figure S3.  
(a) Representative images of collagen gels incubated with KC, KPC or KTC pancreatic epithelial 
tumor cells or with KTC cells treated with vehicle or the ROCK inhibitor Y27632.  Bar 
graphs quantifying the mean collagen fiber diameter in the three-dimensional collagen gels 
described in a. (b) Representative immunoblot showing ROCK protein levels in KTC tumor cells 
expressing either a control shRNA or an shRNA to ROCK. Results are normalized to GAPDH. 
 Bar graph showing the quantification of b. (c) Representative bioluminescence images of 
tumor growth in nude mice 3 weeks after injection with KC, KPC, KTC and KTC pancreatic 
tumor cells expressing either a control shRNA or an shRNA to ROCK. Bar graph showing 
the weight of the pancreatic tumors generated by the KC, KPC and KTC pancreatic epithelial 
cancer cells. ( ) and ( ) Bar graphs quantifying CTGF mRNA expression for pancreatic 
-actin. For in vitro bar graphs, results are the 
mean +/- SEM of at least 3 independent experiments. For in vivo experiments, N=5 mice per 
group. (*p<0.05; **p<0.01, ***p<0.001, ****p<  
Figure S4.  
(a) Representative immunofluorescence images of pancreatic tissue excised from 8 week old 
KC, KPC and KTC mice stained for pStat3 (red) and DAPI (blue). Scale bar, 50µm.  Bar 
graphs quantifying the level of stromal versus epithelial pStat3 in the tissues stained in a. (b) 
Representative images of three-dimensional collagen gels incubated with KTC pancreatic 
epithelial tumor cells for 24 hours either with vehicle or the JAK inhibitor Ruxolitinib. (c) 
Representative images of three-dimensional collagen gels incubated with KC tumor cells treated 
with vehicle or the conditioned media from 48 hour cultured KTC tumor cells. (d) 
Representative immunoblot showing total (Stat3) and activated Stat3 (pStat3) levels in KTC 
tumor cells cultured on soft or stiff polyacrylamide substrates.  Bar graph showing the 
quantification of d. (e) Representative cytokines array images measured in the conditioned media 
of KC and KTC cells cultured on soft or soft polyacrylamide substrates. For in vitro bar graphs, 
results are the mean +/- SEM of at least 3 independent experiments. For in vivo experiments, 
N=5 mice per group. (*p<0.05; **p<0.01, ***p<0.001, ****p<
significant). 
Figure S5.  
(a) Graphic of mouse manipulations used to study the impact of  expression in the 
pancreatic epithelium on tissue fibrosis. (b) Representative immunofluorescence images of 
pancreatic tissues excised from 3 month old control and  mice stained for p397FAK (top 
panel; red) and pMLC2 (2nd panel; red), pStat3 (5th panel; red), scale bar, 50 µm, CD45 (6th 
panel; red) and CD68 (7th panel; red), scale bar, 100µm,  and DAPI (blue). (b) (3rd panel) 
Representative polarized light images of collagen fibers revealed by picrosirius red (PR) staining 
of pancreatic tissue described above. Scale bar, 75µm. (b) (4th panel) Representative force maps 
of ECM stiffness measured using AFM indentation in pancreatic tissue described above. (b ) Bar 
graphs quantifying the tissue images shown in the panels in b. (c) Bar graphs quantifying CTGF 
mRNA expression for pancreatic tissue shown in b. Results a -actin. (d) Bar 
graphs showing quantification of total pancreatic CD45+ and Ly6C immune cells as determined 
(e). Representative cytokines array images measured in pancreatic tissue 
shown in b. ) Bar graphs showing quantification of cytokine levels shown in e. 
Figure S6.  
(a) Representative immunofluorescence images of 6 week old pancreatic tissue excised from 
-1186 stained for p397FAK (top 
panel; red), pMLC2 (2nd panel; red), pStat3 (5th panel; red), scale bar, 50 µm, CD45 (6th panel), 
CD68 (7th panel; red) and DAPI (blue). Scale bar, 100µm. (a) (3rd panel) Representative 
polarized light images of collagen fibers revealed by PR staining of pancreatic tissue described 
above. Scale bar, 75µm. (a) (4th panel) Representative maps of ECM stiffness measured using 
AFM indentation in pancreatic tissue described above. ) Bar graphs quantifying the tissue 
images shown in the panels in a. 
Figure S7.  
(a) Representative immunoblot showing FAK level in KTC tumor cells expressing either a 
control shRNA or an shRNA to FAK. Results are normalized to GAPDH. ). Bar graph 
showing the quantification of a. (b) Representative bioluminescence images of tumor growth in 
nude mice 3 weeks after injection with KTC pancreatic tumor cells expressing either a control 
shRNA or an shRNA to FAK. (c) Bar graphs showing quantification of total pancreatic Ly6C 
(d) Representative cytokines array 
). Bar graph showing the 
quantification of d. 
Figure S8.  
(a) Representative immunofluorescence images of pancreatic tissues excised from 5 week old 
control, KC and homozygous KTC (KTC KO) mice stained for LOX (top panel; red), scale bar 
50 µm, YAP (3rd  panel, red), p397FAK (4th panel, red) and p-MLC2 (5th anel, red) and pStat3 (6th 
panel, red) scale bar 20 µm, and DAPI (blue). (a) (2nd panel) Representative polarized light 
images of collagen fibers revealed by PR staining of pancreatic tissue described above. Scale bar, 
75µm. a'. Bar graphs quantifying the tissue images shown in the panels in a. (b) Quantification of 
ECM stiffness measured by AFM in pancreatic tissue shown in a. For in vivo experiments, N=5 
mice per group. (*p<0.05; **p<0.01, ***p<0.001, ****p< ). 
Figure S9.  
(a) Representative immunofluorescence images of pancreatic tissues excised from 5 week old 
control and Stat3C mice stained for pStat3 (top panel; red), scale bar, 75 µm, p397FAK (2nd panel; 
red) and pMLC2 (3rd panel; red), Scale bar, 50 µm, CD45 (5th panel; red), CD68 (6th panel; red), 
and DAPI (blue). Scale bar, 100µm. (a). (4th panel) Representative polarized light images of 
collagen fibers revealed by PR staining of pancreatic tissue described above. Scale bar, 75µm. 
(a) (7th panel) Representative phase contrast images of H&E stained pancreatic tissue as 
described above. Scale bar, 100µm. ) Bar graphs quantifying the tissue images shown in the 
panels in a. (b) Bar graphs quantifying CTGF mRNA expression for pancreatic tissue excised 
from 5 week  old homozygous KTC (KTC KO) (Control) and KTC/Stat3 KO mice (Stat3 KO). 
Results a -actin. (c) Immunofluorescence confocal images of pancreatic tissues 
from 6 week old KTC (het) mice treated with either vehicle or the JAK inhibitor Ruxolitinib 
stained for pStat3 (top panel; red), scale bar, 75 µm, p397FAK (2nd panel; red) and pMLC2 (3rd d 
panel; red), scale bar, 50 µm, CD45 (5th panel; red), CD68 (6th panel; red), scale bar, 100 µm, 
and DAPI (blue). (c) (4th panel) Representative polarized light images of collagen fibers revealed 
by PR staining of pancreatic tissue described above. Scale bar, 75µm. (c) (7th panel) 
Representative phase contrast images of H&E stained pancreatic tissue as described above. Scale 
bar, 100µm. (c ). Bar graphs quantifying the tissue images shown in the panels in c. (d) 
Quantification of ECM stiffness measured by AFM in pancreatic tissue shown in c. (e) bar 
graphs quantifying the weight of the pancreatic tumors shown in c. For in vivo experiments, N=5 
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